Browse our 650+ Publications​

Latest Publications

Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma(MOLTO): a multicentre, single-arm, phase 2 trial

Tedeschi A, et al.
Lancet Oncology
September 2024
Authors and Affiliates
Alessandra Tedeschi*, Anna Maria Frustaci*, Adalgisa Condoluci, Marta Coscia, Roberto Chiarle, Pier Luigi Zinzani, Marina Motta, Gianluca Gaidano, Giulia Quaresmini, Lydia Scarfò, Gioacchino Catania, Marina Deodato, Rebecca Jones, Valentina Tabanelli, Valentina Griggio, Georg Stüssi, Angelica Calleri, Katia Pini, Roberto Cairoli, Thorsten Zenz, Alessio Signori, Emanuele Zucca, Davide Rossi, Marco Montillo Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Niguarda Cancer Center, Milan, Italy (A Tedeschi MD, A M Frustaci MD, M Deodato MD, R Cairoli MD, M Montillo MD); Department of Oncology, Institute of Oncology Research, Bellinzona, Switzerland (A Condoluci MD, Prof D Rossi MD, K Pini BS, Prof E Zucca MD); Clinic of Hematology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland (A Condoluci, Prof D Rossi, Prof G Stüssi MD, Prof E Zucca MD); University Division of Hematology, AOU Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Turin, Italy (R Jones MD, V Griggio PhD); Department of Oncology ASST Sette Laghi,\ Ospedale di Circolo, Varese, Italy (Prof M Coscia MD);Division of Hematopathology, IEO European Institute of Oncology IRCCS, Milan, Italy (Prof R Chiarle MD, V Tabanelli MD, A Calleri PhD); Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy (Prof R Chiarle); Department of Pathology, Boston Children’s Hospital, Boston, MA, USA (Prof R Chiarle); Azienda Ospedaliero–Universitaria di Bologna, Istituto di Ematologia “L e A Seràgnoli”, Bologna, Italy

Longitudinal study of immunity to SARS-CoV2 inocrelizumab-treated MS patients up to 2 years after COVID-19 vaccination

Kister I., et al.
Annals of Clinical and Translational Neurology
August 2024
Authors and Affiliates
Ilya Kister, Ryan Curtin, Amanda L. Piquet, Tyler Borko, Jinglan Pei, Barbara L Banbury, Tamar E. Bacon, Angie Kim, Michael Tuen, Yogambigai Velmurugu, Samantha Nyovanie, Sean Selva, Marie I. Samanovic, Mark J. Mulligan, Yury Patskovsky, Jessica Priest, Mark Cabatingan, Ryan C. Winger, Michelle Krogsgaard & Gregg J. Silverman

Case report of fatal immune-mediatedmyocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependentCD28 costimulator and dualPD-L1/CTLA-4checkpoint inhibitor, incombination with pembrolizumab

Cavalcante L., et al.
Journal for ImmunoTherapy of Cancer
August 2024
Authors and Affiliates
Ludimila Cavalcante, Sreenivasa Chandana, Nehal Lakhani, Amanda Enstrom, Heidi LeBlanc, Joseph Schmalz, Krisztina Lengyel, Frank Schneider, Heather Thomas, Michael J Chisamore, Stanford L Peng, Allison Naumovski, Diwakar Davar.

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Touzeau C, et al.
Blood
August 2024
Authors and Affiliates
Cyrille Touzeau (University hospital, France) Amrita Krishnan (City of Hope Comprehensive Cancer Center, United States) Philippe Moreau (Hematology, University Hospital Hôtel-Dieu, France) Aurore Perrot (CHU Toulouse - IUCT Oncopole, France) Saad Usmani (Memorial Sloan Kettering Cancer Center, United States) Salomon Manier (CHU Lille, France) Michele Cavo (Seràgnoli Institute of Hematology; Bologna University School of Medicine, Bologna, Italy, Italy) Carmen Martinez Chamorro (Hospital Universitario Quirón Pozuelo, Spain) Ajay Nooka (Emory University Winship Cancer Institute, United States) Thomas Martin (UCSF, United States) Lionel Karlin (Hôpital Lyon Sud, France) Xavier Leleu (Hopital La Miletrie, France) Nizar Bahlis (Arnie Charbonneau Cancer Institute, University of Calgary, Canada) Britta Besemer (University Hospital of Tuebingen, Germany) Lixia Pei (Janssen R&D, United States) Sarah Stein (Janssen R&D US, United States) Shun Xin Wang Lin (Janssen Research & Development, United States) Danielle Trancucci (Janssen Research & Development, United States) Raluca Verona (Janssen Research & Development, United States) Suzette Girgis (Janssen Research & Development, LLC, United States) Xin Miao (Janssen Research & Development, LLC, United States) Clarissa Uhlar (Janssen R&D, United States) Katherine Chastain (Janssen Research & Development, LLC, United States) Alfred Garfall (University of Pennsylvania, United States)

Safety and efficacy of belantamab mafodotin with pembrolizumab in patients with relapsed or refractory multiple myeloma

Suvannasankha A, et al.
Cancer
August 2024
Authors and Affiliates
Attaya Suvannasankha MD1 | Nizar Bahlis MD2 | Suzanne Trudel MSc, MD3 | Katja Weisel MD4 | Christian Koenecke MD5 | Albert Oriol MD, PhD6 | Peter M. Voorhees MD7 | Aranzazu A. Alonso MD8 | Natalie S. Callander MD9 | María‐Victoria Mateos MD, PhD10 | Nishitha Reddy MD11 | Shawn Hakim PhD12 | John LaMacchia MD, PhD13 | Nashita Patel MSc, PhD14 | Danaé Williams MSc12 | Roxanne C. Jewell PhD15 | Xiangdong Zhou PhD12 | Ira Gupta MD16 | Joanna Opalinska MD12 | Ajay K. Nooka MD, MPH, FACP17 1 Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, Indiana, USA 2 Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Alberta, Canada 3 Princess Margaret Cancer Centre, Toronto, Ontario, Canada 4 University Medical Center Hamburg‐Eppendorf, Hamburg, Germany 5 Hannover Medical School, Clinic for Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover, Germany 6 Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Barcelona, Spain 7 Levine Cancer Institute, Atrium Health/Wake Forest University School of Medicine, Charlotte, North Carolina, USA 8 Hospital Universitario Quirónsalud Madrid, Madrid, Spain 9 Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin, USA 10Instituto de Investigación Biomédica de Salamanca and Centro de Investigación del Cáncer, Hospital Universitario de Salamanca, Salamanca, Spain 11Merck & Co., Inc, Rahway, New Jersey, USA 12GlaxoSmithKline, Upper Providence, Pennsylvania, USA 13GlaxoSmithKline, Waltham, Massachusetts, USA 14GlaxoSmithKline, Stevenage, UK 15GlaxoSmithKline, Durham, North Carolina, USA 16GlaxoSmithKline, Philadelphia, Pennsylvania, USA 17Winship Cancer Institute, Emory University Hospital, Atlanta, Georgia, USA

Broader anti-EBV TCR repertoire in multiple sclerosis: disease specificity and treatment modulation

Schneider-Hohendorf, et al.
Brain
July 2024
Authors and Affiliates
Tilman Schneider-Hohendorf, Christian Wünsch, Simon Falk, Catarina Raposo, Florian Rubelt, Hamid Mirebrahim, Hosseinali Asgharian, Ulrich Schlecht, Daniel Mattox, Wenyu Zhou, Eva Dawin, Marc Pawlitzki, Sarah Lauks, Sven Jarius, Brigitte Wildemann, Joachim Havla, Tania Kümpfel, Miriam-Carolina Schrot, Marius Ringelstein, Markus Kraemer, Carolin Schwake, Thomas Schmitter, Ilya Ayzenberg, Katinka Fischer, Sven G. Meuth, Orhan Aktas, Martin W. Hümmert, Julian R. Kretschmer, Corinna Trebst, Ilka Kleffner, Jennifer Massey, Paolo A. Muraro, Haiyin Chen-Harris, Catharina C. Gross, Luisa Klotz, Heinz Wiendl and Nicholas Schwab

A Phase 1 Clinical Trial of NKTR-255 with CD19-22 CAR-T Cell Therapy for Refractory B-cell Acute Lymphoblastic Leukemia

Srinagesh H, et al.
Blood
July 2024
Authors and Affiliates
Hrishikesh Srinagesh1 , Clayton Jackson2 , Parveen Shiraz3 , Nikeshan Jeyakumar1 , Mark Hamilton1 , Emily Egeler4 , Sharon Mavroukakis4 , Adam Kuo4 , Juancarlos Cancilla4 , Bita Sahaf4 , Neha Agarwal3 , Alyssa Kanegai3 , Anne Marijn Kramer3,4 , Sally Arai3 , Sushma Bharadwaj3 , Saurabh Dahiya3 , Hitomi Hosoya3 , Laura Johnston3 , Vanessa Kennedy3 , Michaela Liedtke1 , Robert Lowsky3 , Lekha Mikkilineni3 , Robert Negrin3 , Andrew Rezvani3 , Surbhi Sidana3 , Judith Shizuru3 , Melody Smith3 , Wen-Kai Weng3 , Steven Feldman4 , Matthew J. Frank3,4 , Zachary Lee5 , Mary Tagliaferri5 , A. Mario Marcondes5 , David Miklos3,4 , Crystal Mackall4 , Lori Muffly3,4 Division of Hematology/Oncology, UT Southwestern, Dallas, TX; 3 Division of Blood and Marrow Transplantation and Cellular Therapy, Stanford University, Stanford CA; 4 Center for Cancer Cell Therapy, Stanford University, Stanford, CA; 5 Nektar Therapeutics, San Francisco, CA

Molecular disease monitoring in patients with relapsed/refractory B-cell lymphoma receiving anti-CD19 CAR T-cell therapy

Colton M, et al.
Clinical Lymphoma Myeloma & Leukemia
June 2024
Authors and Affiliates
Colton, Meryl MD MSc1; Purev, Enkhtsetseg MD1; Haverkos, Bradley MD MPH1; Bair, Steven MD1; Jasem, Jagar MD MPH1; Allison Jacob MS2; Kamdar, Manali MD1 1. Division of Hematology, Hematologic Malignancies and Stem Cell Transplantation, University of Colorado Cancer Center, Aurora, CO 2. Adaptive Biotechnologies, Seattle WA

Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma

Melani C, et al.
New England Journal of Medicine
June 2024
Authors and Affiliates
C. Melani, R. Lakhotia, S. Pittaluga, J.D. Phelan, D.W. Huang, G. Wright, J. Simard, J. Muppidi, C.J. Thomas, M. Ceribelli, F.A. Tosto, Y. Yang, W. Xu, T. Davies‑Hill, S.D. Pack, C.J. Peer, O. Arisa, E. Mena, L. Lindenberg, E. Bergvall, C.A. Portell, R.J. Farah, S.T. Lee, A. Pradhan, C. Morrison, A. Tadese, A.M. Juanitez, C. Lu, A. Jacob, H. Simmons, W.D. Figg, S.M. Steinberg, E.S. Jaffe, M. Roschewski, L.M. Staudt, and W.H. Wilson Lymphoid Malignancies Branch (C. Melani, R.L., J.D.P., D.W.H., J.S., J.M., Y.Y., W.X., A.P., C. Morrison, A.T., A.M.J., M.R., L.M.S., W.H.W.), the Clinical Pharmacology Program (C.J.P., O.A., W.D.F.), the Molecular Imaging Branch (E.M., L.L., E.B.), and the Biostatistics and Data Management Section (S.M.S.), Center for Cancer Research, the Laboratory of Pathology, Clinical Center (S.P., T.D.-H., S.D.P., E.S.J.), and the Biometric Research Program, Division of Cancer Treatment and Diagnosis (G.W.), National Cancer Institute, the Division of Pre-Clinical Innovation Chemistry Technologies, National Center for Advancing Translational Sciences (C.J.T., M.C., F.A.T.), and the Clinical Center Pharmacy Department (C.L.), National Institutes of Health, Bethesda, and Greenebaum Comprehensive Cancer Center, University of Maryland Medical Center, Baltimore (S.T.L.) — all in Maryland; the Division of Hematology and Oncology, University of Virginia, Charlottesville (C.A.P.); Mario Lemieux Center for Blood Cancers, University of Pittsburgh School of Medicine, Pittsburgh (R.J.F.); and Adaptive Biotechnologies, Seattle (A.J., H.S.)

Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma

Bumma N, et al.
Journal of Clinical Oncology
June 2024
Authors and Affiliates
Naresh Bumma, MD1; Joshua Richter, MD2 ; Sundar Jagannath, MD2 ; Hans C. Lee, MD3 ; James E. Hoffman, MD4; Attaya Suvannasankha, MD5 ; Jeffrey A. Zonder, MD6 ; Mansi R. Shah, MD7 ; Suzanne Lentzsch, MD, PhD8 ; Rachid Baz, MD9 ; Joseph J. Maly, MD10; Swathi Namburi, MD11; Matthew J. Pianko, MD12 ; Jing Christine Ye, MD, MS12; Ka Lung Wu, MD, PhD13 ; Rebecca Silbermann, MD14 ; Chang-Ki Min, MD15; Marie-Christiane Vekemans, MD16; Markus Munder, MD17 ; Ja Min Byun, MD18 ; Joaqu´ın Mart´ınez-Lopez, MD19 ; Kaniel Cassady, PhD20 ; Michelle DeVeaux, PhD20; Dhruti Chokshi, BS20; Anita Boyapati, PhD20; Anasuya Hazra, PhD20; George D. Yancopoulos, MD, PhD20; L. Andres Sirulnik, MD, PhD20; Karen Rodriguez Lorenc, MD20; Glenn S. Kroog, MD20 ; Yariv Houvras, MD, PhD20; and Madhav V. Dhodapkar, MD21 1The Ohio State University Comprehensive Cancer Center, Columbus, OH 2Icahn School of Medicine at Mount Sinai, New York, NY 3The University of Texas MD Anderson Cancer Centre, Houston, TX 4University of Miami Health System, Miami, FL 5Indiana University Simon Cancer Center and Roudebush VAMC, Indianapolis, IN 6Karmanos Cancer Institute, Detroit, MI 7Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 8Columbia University Medical Center, New York, NY 9Department of Malignant Hematology, H. Lee Moffitt Cancer Center, Tampa, FL 10Norton Cancer Institute, Louisville, KY 11Swedish Cancer Institute, Seattle, WA 12Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, MI 13Ziekenhuis Netwerk Antwerpen Stuivenberg, Antwerp, Belgium 14Knight Cancer Institute, Oregon Health & Science University, Portland, OR 15Department of Hematology, College of Medicine, Catholic Hematology Hospital and Leukemia Research Institute, Seoul St Mary’s Hospital, The Catholic University of Korea, Seoul, South Korea 16Department of Hematology, Cliniques Universitaires Saint-Luc, Universit´e Catholique de Louvain (UCLouvain), Brussels, Belgium 17Department of Internal Medicine III, University Medical Center Mainz, Mainz, Germany 18Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul, Korea 19Hospital 12 de Octubre, i112, School of Medicine Universidad Complutense, CNIO, Madrid, Spain 20Regeneron Pharmaceuticals, Inc, Tarrytown, NY 21Emory University School of Medicine, Atlanta, GA
Previous Next